In addition, an increasing number of studies have recently shown that SRSF2 gene mutation and dysregulated SRSF2 expression are significantly associated with acute myeloid leukemia (AML) 16, 17, myelodysplastic syndromes 18-20, systemic mastocytosis 21, 22, chronic myelomonocytic leukemia 23-25, lung carcinoma 26, 27, hepatocellular carcinoma 28, and sinonasal squamous cell carcinoma 29. Here, SRSF2 is linked to systemic mastocytosis.